StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a note issued to investors on Friday. The firm set a “hold” rating on the stock.

Oncternal Therapeutics Price Performance

Shares of ONCT opened at $0.53 on Friday. The company has a 50-day moving average of $0.53 and a two-hundred day moving average of $2.05. The stock has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18. Oncternal Therapeutics has a one year low of $0.53 and a one year high of $13.14.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.